Human medicines European public assessment report (EPAR): Constella, linaclotide, Date of authorisation: 26/11/2012, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Constella, linaclotide, Date of authorisation: 26/11/2012, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Cimzia, certolizumab pegol, Date of authorisation: 01/10/2009, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Cimzia, certolizumab pegol, Date of authorisation: 01/10/2009, Revision: 40, Status: Authorised

Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Date of authorisation: 12/01/2005, Revision: 68, Status: Authorised

Human medicines European public assessment report (EPAR): Avastin, bevacizumab, Date of authorisation: 12/01/2005, Revision: 68, Status: Authorised

Quarterly System Demo - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 June 2026, 09:00 (CEST) to 25 June 2026, 12:30 (CEST)

Quarterly System Demo - Q2 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 June 2026, 09:00 (CEST) to 25 June 2026, 12:30 (CEST)

Quarterly System Demo - Q3 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 September 2026, 09:00 (CEST) to 17 September 2026, 12:30 (CEST)

Quarterly System Demo - Q3 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 September 2026, 09:00 (CEST) to 17 September 2026, 12:30 (CEST)

Quarterly System Demo - Q4 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 10 December 2026, 09:00 (CET) to 10 December 2026, 12:30 (CET)

Quarterly System Demo - Q4 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 10 December 2026, 09:00 (CET) to 10 December 2026, 12:30 (CET)

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.